LipoMedix is a development-stage privately held company focused on the development of an innovative, safe and effective cancer therapy based on liposome delivery.
The Company was established in order to advance the pharmaceutical and clinical development of a patented new chemical entity prodrug of mitomycin-C and its efficient delivery in liposomes to cancer-affected target organs. This formulation known as Promitil® – Pegylated Liposomal Mitomycin-C Prodrug (PL-MLP) – overcomes the problems associated with mitomycin-C toxicity and turn it into a state-of-the-art anti-cancer drug that will potentially become the therapy of choice in a variety of cancers, especially those derived from the gastrointestinal tract (stomach, pancreas, colorectal). The inventor and scientific founder, of LipoMedix is Prof. Alberto Gabizon of the Hebrew University – Shaare Zedek Medical Center who is also the co-inventor and co-developer of Doxil®, (the first FDA-approved nano-drug in cancer therapy). As co-developer of Doxil® Prof. Gabizon is one of the few scientists intimately familiar with the successful development & commercialization process of liposomal drugs.
Promitil® is an innovative chemotherapeutic agent with distinct advantages over conventional anticancer agents that have adverse side effects and fail to be effective after a relatively short period of time. This innovative and breakthrough technology will enable cancer patients to receive safer therapy with a more potent anti-tumor effect.